WHAT IS PRIMARY dRTA?
Primary distal renal tubular acidosis (primary dRTA) is a rare genetic condition that results in problems with kidney function, bone formation, hearing, and the management of potassium, calcium, and pH levels in the body. The symptoms of primary dRTA most often appear in babies; however, there are rarer forms of the disorder that start in older children and adults.
What is the ARENA2 dRTA Study?
ARENA2 is a Phase III clinical study that is expected to include approximately 40 patients in the United States and Canada. The principal objective of the clinical study is to evaluate the safety and efficacy of ADV7103 versus placebo in preventing the development of metabolic acidosis in patients with primary dRTA.
dRTA Communities and Resources
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephroloy. Our lead drug candidate, ADV7103, is in late-stage clinical trials for primary distal renal tubular acidosis (dRTA). Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Paris, France.
You are not alone. Connect with other members of the dRTA community on social media and with organizations providing education and support.
ADV7103 is an investigational product and has not been demonstrated to be safe and effective in the US population.